A Phase 3 interventional study of mRNA-1083 and Placebo in SARS-CoV-2 and Influenza, sponsored by ModernaTX, Inc.. Completed at 146 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 4th largest by enrollment, is one of 6 that started in 2023, is one of 7 in phase 3, and was the 16th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 7 · Phase 4 1
First in 2015; this study’s year is marked. 6 started in 2023.
This study's enrollment of 8,061 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 885 across the 23 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
2 of the studies in Influenza, Human by Moderna, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Influenza, Human by Moderna, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Key Inclusion Criteria:
Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants of age 65 years and older will receive mRNA-1083 and placebo administered as 2 intramuscular (IM) injections of on Day 1.
Biological: mRNA-1083 · Biological: Placebo
Participants of age 65 years and older will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.
Biological: Influenza Vaccine · Biological: COVID-19 Vaccine
Participants of age 50 to \<65 years will receive mRNA-1083 and placebo administered as 2 IM injections of on Day 1.
Biological: mRNA-1083 · Biological: Placebo
Participants of age 50 to \<65 years will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.
Biological: Influenza Vaccine · Biological: COVID-19 Vaccine
Suspension for injection
0.9% sodium chloride suspension for injection
Commercially available formulation (Suspension for injection \[pre-filled syringe\])
Commercially available formulation (Suspension for injection)
Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The Per Protocol Immunogenicity Set (PPIS) included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative reverse transcription polymerase chain reaction (RT-PCR) test for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Day 29
GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Day 29
Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a Day 29 postinjection level ≥1:40 if Baseline was \<1:10 or a 4-fold or greater rise if Baseline was ≥1:10 in anti-hemagglutinin (HA) antibodies measured by HAI assay. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Baseline to Day 29
SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as a Day 29 postinjection level ≥4-fold rise if Baseline was ≥lower limit of quantification (LLOQ) or ≥4×LLOQ if Baseline value was \<LLOQ in the nAb values measured by PsVNA. LLOQ was 38 arbitrary unit (AU)/milliliter (mL). The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Baseline to Day 29
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 7 days after study injection
Number of Participants With Unsolicited Adverse Events (AEs)
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 28 days after study injection
Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 181
Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Day 1, Day 29
GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Day 1, Day 29
GM Level of Antibodies for Influenza, as Measured by Microneutralization (MN) Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Day 29
GMFR of Antibodies for Influenza, as Measured by MN Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
Time frame: Day 1, Day 29
Number of Deaths Related to Study Drug mRNA-1083 and Placebo
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.
Time frame: Day 1 through Day 181
Number of Deaths Related to Control Drug Influenza Vaccine and COVID-19 Vaccine
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.
Time frame: Day 1 through Day 181
| Milestone | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Started | 2025 | 2012 | 2009 | 2015 |
| Received both injections | 2011 | 2006 | 1993 | 2005 |
| Completed | 1974 | 1977 | 1944 | 1957 |
| Not completed | 51 | 35 | 65 | 58 |
| Withdrew: Death | 2 | 1 | 2 | 2 |
| Withdrew: Lost to follow-up | 27 | 18 | 36 | 31 |
| Withdrew: Physician decision | 0 | 1 | 0 | 3 |
| Withdrew: Protocol violation | 1 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 14 | 11 | 14 | 15 |
| Withdrew: Other than specified | 7 | 3 | 11 | 6 |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The Per Protocol Immunogenicity Set (PPIS) included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative reverse transcription polymerase chain reaction (RT-PCR) test for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| titer | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Influenza A H1N1 Antibody | 120.5 (116.0 to 125.2) | 104.3 (100.4 to 108.4) | 137.7 (132.1 to 143.5) | 97.3 (93.4 to 101.5) |
| Influenza A H3N2 Antibody | 114.7 (110.4 to 119.2) | 107.9 (103.9 to 112.1) | 111.5 (107.5 to 115.7) | 80.8 (77.9 to 83.8) |
| Influenza B Victoria-lineage Antibody | 245.3 (237.8 to 252.9) | 219.4 (212.8 to 226.3) | 224.9 (218.0 to 232.0) | 185.0 (179.3 to 190.8) |
| Influenza B Yamagata-lineage Antibody | 93.3 (91.1 to 95.6) | 92.6 (90.4 to 94.9) | 101.7 (99.3 to 104.3) | 88.1 (86.0 to 90.3) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| titer | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA) | 1396.7 (1326.6 to 1470.5) | 851.1 (808.6 to 895.9) | 1551.6 (1476.3 to 1630.7) | 1186.1 (1128.5 to 1246.7) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a Day 29 postinjection level ≥1:40 if Baseline was \<1:10 or a 4-fold or greater rise if Baseline was ≥1:10 in anti-hemagglutinin (HA) antibodies measured by HAI assay. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| percentage of participants | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Influenza A H1N1 Antibody | 36.4 (34.3 to 38.7) | 31.1 (29.0 to 33.2) | 50.6 (48.3 to 52.9) | 32.7 (30.6 to 34.8) |
| Influenza A H3N2 Antibody | 38.7 (36.5 to 40.9) | 34.6 (32.5 to 36.8) | 41.9 (39.7 to 44.2) | 27.4 (25.4 to 29.5) |
| Influenza B Victoria-lineage Antibody | 23.9 (22.0 to 25.9) | 19.4 (17.6 to 21.2) | 25.8 (23.9 to 27.9) | 17.2 (15.5 to 19.0) |
| Influenza B Yamagata-lineage Antibody | 8.8 (7.5 to 10.1) | 10.2 (8.9 to 11.7) | 13.0 (11.5 to 14.6) | 10.3 (9.0 to 11.8) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as a Day 29 postinjection level ≥4-fold rise if Baseline was ≥lower limit of quantification (LLOQ) or ≥4×LLOQ if Baseline value was \<LLOQ in the nAb values measured by PsVNA. LLOQ was 38 arbitrary unit (AU)/milliliter (mL). The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| percentage of participants | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA | 82.3 (80.5 to 84.1) | 69.6 (67.4 to 71.7) | 84.6 (82.8 to 86.2) | 76.5 (74.5 to 78.4) |
Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Any | 1681 | 1565 | 1698 | 1640 |
| Grade 3 or Grade 4 | 183 | 84 | 246 | 127 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Number of Participants With Unsolicited Adverse Events (AEs) | 239 | 250 | 195 | 191 |
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| SAEs | 70 | 52 | 29 | 27 |
| AESIs | 18 | 13 | 4 | 9 |
| MAAEs | 426 | 428 | 301 | 304 |
| AEs Leading to Discontinuation | 0 | 0 | 1 | 0 |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| ratio | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Influenza A H1N1 Antibody | 2.70 (2.60 to 2.81) | 2.36 (2.26 to 2.46) | 3.70 (3.54 to 3.86) | 2.54 (2.43 to 2.66) |
| Influenza A H3N2 Antibody | 2.78 (2.67 to 2.89) | 2.59 (2.48 to 2.70) | 3.07 (2.95 to 3.19) | 2.22 (2.13 to 2.31) |
| Influenza B Victoria-lineage | 2.05 (1.98 to 2.12) | 1.84 (1.77 to 1.90) | 2.13 (2.06 to 2.20) | 1.75 (1.69 to 1.81) |
| Influenza B Yamagata-lineage | 1.52 (1.48 to 1.55) | 1.52 (1.48 to 1.56) | 1.71 (1.66 to 1.75) | 1.48 (1.44 to 1.52) |
SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| ratio | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA | 16.86 (15.87 to 17.93) | 10.32 (9.72 to 10.96) | 17.83 (16.78 to 18.94) | 13.56 (12.72 to 14.46) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| titer | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Influenza A H1N1 Antibody | 676.4 (528.8 to 865.3) | 635.9 (489.4 to 826.4) | 946.8 (729.7 to 1228.4) | 428.1 (327.0 to 560.4) |
| Influenza A H3N2 Antibody | 587.6 (483.9 to 713.6) | 668.8 (538.9 to 830.0) | 645.8 (519.1 to 803.5) | 393.9 (324.7 to 477.9) |
| Influenza B Victoria-lineage Antibody | 2845.4 (2406.1 to 3364.9) | 3072.5 (2571.0 to 3671.9) | 2901.5 (2457.6 to 3425.6) | 1883.1 (1571.4 to 2256.5) |
| Influenza B Yamagata-lineage Antibody | 1118.8 (910.4 to 1374.9) | 1434.4 (1200.9 to 1713.3) | 1449.6 (1222.5 to 1719.0) | 1071.3 (883.8 to 1298.4) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.
| ratio | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Influenza A H1N1 Antibody | 4.89 (3.92 to 6.10) | 4.68 (3.68 to 5.94) | 8.74 (7.03 to 10.87) | 5.14 (4.01 to 6.60) |
| Influenza A H3N2 Antibody | 2.88 (2.44 to 3.41) | 2.46 (2.01 to 3.01) | 3.33 (2.76 to 4.01) | 1.94 (1.64 to 2.31) |
| Influenza B Victoria-lineage | 3.22 (2.63 to 3.94) | 3.02 (2.48 to 3.67) | 3.87 (3.27 to 4.58) | 3.27 (2.66 to 4.02) |
| Influenza B Yamagata-lineage | 2.98 (2.56 to 3.46) | 3.38 (2.75 to 4.15) | 3.66 (3.02 to 4.44) | 3.42 (2.79 to 4.19) |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.
| Participants | Cohort A1: mRNA-1083 and Placebo | Cohort B1: mRNA-1083 and Placebo |
|---|---|---|
| Deaths | 2 | 2 |
| Deaths Related to Study Drug mRNA-1083 | 0 | 0 |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.
| Participants | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|
| Deaths | 1 | 2 |
| Deaths Related to Control Drug | 0 | 0 |
Collected over Day 1 through Day 181. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A1: mRNA-1083 and Placebo | 2/2,025 (0.1%) | 71/2,011 (3.5%) | 0/2,011 (0%) |
| Cohort A2: Influenza Vaccine and COVID-19 Vaccine | 1/2,012 (0%) | 52/2,006 (2.6%) | 0/2,006 (0%) |
| Cohort B1: mRNA-1083 and Placebo | 2/2,009 (0.1%) | 29/1,993 (1.5%) | 0/1,993 (0%) |
| Cohort B2: Influenza Vaccine and COVID-19 Vaccine | 2/2,015 (0.1%) | 27/2,005 (1.3%) | 0/2,005 (0%) |
| Event | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine |
|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/2011 | 2/2006 | 0/1993 | 1/2005 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/2011 | 0/2006 | 3/1993 | 0/2005 |
| PneumoniaInfections and infestations | 1/2011 | 3/2006 | 1/1993 | 3/2005 |
| Atrial fibrillationCardiac disorders | 2/2011 | 3/2006 | 0/1993 | 1/2005 |
| Cerebrovascular accidentNervous system disorders | 3/2011 | 0/2006 | 0/1993 | 0/2005 |
| Non-cardiac chest painGeneral disorders | 3/2011 | 0/2006 | 1/1993 | 0/2005 |
| Post-traumatic stress disorderPsychiatric disorders | 0/2011 | 0/2006 | 2/1993 | 0/2005 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/2011 | 1/2006 | 2/1993 | 2/2005 |
| Cardiac arrestCardiac disorders | 0/2011 | 2/2006 | 1/1993 | 2/2005 |
| Hypertensive urgencyVascular disorders | 0/2011 | 0/2006 | 0/1993 | 2/2005 |
The randomization set included all participants who were randomly assigned. Participants were included in the treatment arm to which they were randomized.
| Age, Continuous(years) | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine | Total |
|---|---|---|---|---|---|
| Mean | 70.9 ± 4.96 | 70.7 ± 4.70 | 57.5 ± 4.25 | 57.4 ± 4.21 | 64.1 ± 8.06 |
| Sex: Female, Male(Participants) | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine | Total |
|---|---|---|---|---|---|
| Female | 1084 | 1100 | 1165 | 1201 | 4550 |
| Male | 941 | 912 | 844 | 814 | 3511 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 284 | 275 | 393 | 381 | 1333 |
| Not Hispanic or Latino | 1701 | 1695 | 1591 | 1613 | 6600 |
| Unknown or Not Reported | 40 | 42 | 25 | 21 | 128 |
| Race/Ethnicity, Customized(Participants) | Cohort A1: mRNA-1083 and Placebo | Cohort A2: Influenza Vaccine and COVID-19 Vaccine | Cohort B1: mRNA-1083 and Placebo | Cohort B2: Influenza Vaccine and COVID-19 Vaccine | Total |
|---|---|---|---|---|---|
| Race — White | 1588 | 1570 | 1382 | 1350 | 5890 |
| Race — Black or African American | 373 | 370 | 522 | 555 | 1820 |
| Race — Asian | 25 | 37 | 52 | 39 | 153 |
| Race — American Indian or Alaska Native | 9 | 12 | 12 | 13 | 46 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 4 | 3 | 5 | 13 |
| Race — Other | 4 | 3 | 4 | 8 | 19 |
| Race — Multiple | 14 | 4 | 19 | 21 | 58 |
| Race — Unknown/Not Reported | 11 | 12 | 15 | 24 | 62 |
Showing the first 100 of 146 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2023 to primary completion in May 2024, 7 months.
Results were first posted in Jun 2025, 1 year after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 7 months is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MRNA-1083